Bernard Coupal
Directeur/Membre du Conseil chez CARDIAnove, Inc.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Richard Bourget | M | - |
CARDIAnove, Inc.
CARDIAnove, Inc. Medical SpecialtiesHealth Technology CARDIAnove, Inc. engages in the design and development of medical device technologies for temporary and permanent support of the failing heart to improve the quality of life and prolong life of patients suffering from severe congestive heart failure. The company was founded by Conrad Pelletier and Michel Carrier in 1997 and is headquartered in Montréal, Canada. | - |
Michel Carrier | M | - |
CARDIAnove, Inc.
CARDIAnove, Inc. Medical SpecialtiesHealth Technology CARDIAnove, Inc. engages in the design and development of medical device technologies for temporary and permanent support of the failing heart to improve the quality of life and prolong life of patients suffering from severe congestive heart failure. The company was founded by Conrad Pelletier and Michel Carrier in 1997 and is headquartered in Montréal, Canada. | 27 ans |
Guy Chamberland | M | - |
CARDIAnove, Inc.
CARDIAnove, Inc. Medical SpecialtiesHealth Technology CARDIAnove, Inc. engages in the design and development of medical device technologies for temporary and permanent support of the failing heart to improve the quality of life and prolong life of patients suffering from severe congestive heart failure. The company was founded by Conrad Pelletier and Michel Carrier in 1997 and is headquartered in Montréal, Canada. | - |
Steven Arless | M | - |
CARDIAnove, Inc.
CARDIAnove, Inc. Medical SpecialtiesHealth Technology CARDIAnove, Inc. engages in the design and development of medical device technologies for temporary and permanent support of the failing heart to improve the quality of life and prolong life of patients suffering from severe congestive heart failure. The company was founded by Conrad Pelletier and Michel Carrier in 1997 and is headquartered in Montréal, Canada. | - |
André Monette | M | 66 |
CARDIAnove, Inc.
CARDIAnove, Inc. Medical SpecialtiesHealth Technology CARDIAnove, Inc. engages in the design and development of medical device technologies for temporary and permanent support of the failing heart to improve the quality of life and prolong life of patients suffering from severe congestive heart failure. The company was founded by Conrad Pelletier and Michel Carrier in 1997 and is headquartered in Montréal, Canada. | - |
Diane Gosselin | F | - |
CARDIAnove, Inc.
CARDIAnove, Inc. Medical SpecialtiesHealth Technology CARDIAnove, Inc. engages in the design and development of medical device technologies for temporary and permanent support of the failing heart to improve the quality of life and prolong life of patients suffering from severe congestive heart failure. The company was founded by Conrad Pelletier and Michel Carrier in 1997 and is headquartered in Montréal, Canada. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Stephen G. Sudovar | M | 77 |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 1 ans |
Bonabes-Olivier de Rougé | M | - |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 5 ans |
Joseph J. Krivulka | M | 73 |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 1 ans |
Philip S. Tabbiner | M | - |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 5 ans |
Luc Tanguay | M | 65 |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 4 ans |
Chandrakant Panchal | M | 74 |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 2 ans |
Max E. Link | M | 84 |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | - |
Hans C. Fluehler | M | - |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | - |
Frédéric Porte | M | - |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | - |
Monique Létourneau | F | - |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 8 ans |
Bertrand Cayrol | M | - |
Société Innovatech du Grand Montréal
| 4 ans |
François Lombard | M | 76 |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 3 ans |
Jinzi Wu | M | 61 |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 4 ans |
Brian Davies | M | - |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | - |
Statistiques
Pays | Relations | % du total |
---|---|---|
Canada | 20 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Bernard Coupal
- Réseau Personnel